公开(公告)号：US12215350B2

公开(公告)日：2025-02-04

申请号：US16796226

申请日：2020-02-20

Applicant: ImmunityBio, Inc.

Inventor： Rohit Duggal ,  Ranjeet Sinha ,  Wenzhao Li ,  Jason Isaacson ,  Karl Marquez ,  Patrick Soon-Shiong

IPC: C12N5/0783 ,  C07K14/54 ,  C07K14/735

Abstract: Cord blood or peripheral blood NK cells are prepared from whole blood mononuclear cells without the need to isolate CD34+ hematopoietic stem cells or NK cells, and without the need for a feeder layer. Advantageously, the methods presented herein use an enrichment process that uses antiCD16 agonist antibodies, antiCD3 antibodies, and N-803. Moreover, contemplated processes are suitable for adaptation into a fully automated production process (GMP in a box).

公开(公告)号：US20240366764A1

公开(公告)日：2024-11-07

申请号：US18649790

申请日：2024-04-29

Applicant: ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong ,  Elizabeth Gabitzsch

IPC: A61K39/00 ,  C07K14/47 ,  C12N5/0783 ,  C12N15/86

Abstract: An immunotherapeutic composition is contemplated that comprises subject-derived peripheral blood mononuclear cells (PBMC) and at least one recombinant adenovirus subtype 5 (Ad5) comprising a deletion in an E1 gene region, a deletion in an E2b gene region, and a nucleic acid sequence encoding a peptide antigen, wherein the PBMC are exposed ex-vivo to the at least one Ad5 vector. Advantageously, the same PBMC composition may also be used to prepare modified NK cells, and especially modified NK include CIML NK cells, CENK cells and mCENK cells.

公开(公告)号：US20240075129A1

公开(公告)日：2024-03-07

申请号：US18488629

申请日：2023-10-17

Applicant: ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong ,  Peter Sieling ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Lise Geissert ,  Annie Shin ,  Adrian Rice ,  Elizabeth Gabitzsch ,  Jeffrey Safrit ,  Leonard Sender

IPC: A61K39/215 ,  C12N15/861

CPC classification number: A61K39/215 ,  C12N15/861 ,  A61P31/14

Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

公开(公告)号：US20250042971A1

公开(公告)日：2025-02-06

申请号：US18783324

申请日：2024-07-24

Applicant: ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong

IPC: C07K14/705 ,  A61K39/00 ,  A61P35/00 ,  C07K14/71 ,  C07K16/24 ,  C07K16/28

Abstract: Provided herein are compositions and methods comprising Leukocyte-associated immunoglobulin-like receptor 2 (LAIR-2) and a Fc domain. Further provided herein are compositions and methods comprising TNT antibody fused to a TGFβ trap. The compositions and methods provided herein are useful for modulating a collagen matrix in a solid tumor.

公开(公告)号：US12168052B2

公开(公告)日：2024-12-17

申请号：US18620192

申请日：2024-03-28

Applicant: ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong

IPC: A61K39/215 ,  A61K39/00 ,  A61P31/14

Abstract: Recombinant SARS-CoV2 vaccine compositions and methods are presented that have unexpected cross-reactivity against a variety of other coronaviruses, and particularly against SARS-CoV1, MERS-CoV, OC43-CoV, and HKU1-CoV in addition to significant reactivity against SARS-CoV2A. Moreover, the vaccine compositions presented herein also produced cross-reactive memory B cells as well as cross-reactive memory T cells with cross-reactivity spanning a relatively wide range of different coronaviruses.

公开(公告)号：US20240016849A1

公开(公告)日：2024-01-18

申请号：US18463907

申请日：2023-09-08

Applicant: ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong ,  Hans G Klingemann ,  Laurent H Boissel ,  Himani Chinnapen ,  Abhijit Dandapat

IPC: A61K35/17 ,  A61K38/17

CPC classification number: A61K35/17 ,  A61K38/1774

Abstract: The present application is directed to methods and compositions that are useful for reducing the number of myeloid-derived suppressor cells (MDSC), tumor associated macrophages (TAM), or both in a subject. The methods include administering an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or administering a modified T cell or NK-92 cell that expresses an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or a combination of both, to a subject. For example, the antigen binding protein can bind to CD33 expressed by MDSC and/or TAM. The methods and compositions are useful for treating a disease associated with MDSC and/or TAM infiltration into a tissue or tumor.

公开(公告)号：US11455385B2

公开(公告)日：2022-09-27

申请号：US17556887

申请日：2021-12-20

Applicant: Nant Holdings IP, LLC ,  ImmunityBio, Inc.

Inventor： Luna Witchey ,  John Zachary Sanborn ,  Patrick Soon-Shiong ,  Nicholas James Witchey

IPC: G06F21/32 ,  G16B50/40 ,  G06F21/60 ,  G06F21/64

Abstract: Authentication tokens, systems, and methods are described. An illustrative method is disclosed to include receiving an electronic file including a digital image, receiving biometric information that is associated with a person, modifying the electronic file with the biometric information such that one or more pixels in the digital image are replaced with the biometric information, and storing the modified electronic file as a digital authentication token to be used in connection with authorized publications of original digital work.

公开(公告)号：US20220257660A1

公开(公告)日：2022-08-18

申请号：US17732190

申请日：2022-04-28

Applicant: NantCell, Inc. ,  NantBio, Inc. ,  ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Hans G. Klingemann

IPC: A61K35/17 ,  A61P35/00 ,  C12N5/0783 ,  C07K14/54

Abstract: Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.

公开(公告)号：US20210284716A1

公开(公告)日：2021-09-16

申请号：US16880804

申请日：2020-05-21

Applicant: ImmunityBio, Inc.

Inventor： Kayvan Niazi ,  C. Anders Olson ,  Shiho Tanaka ,  John H. Lee ,  Wendy Higashide ,  Patrick Soon-Shiong

IPC: C07K14/81

Abstract: An ACE2-Fc hybrid construct is used as a therapeutic and/or analytic entity to treat an individual infected with a coronavirus or to detect a coronavirus in an analyte. In selected embodiments, the Fc portion of the hybrid construct is an IgA Fc portion, and in still further embodiments the ACE2 portion has a mutation that reduces or abolishes ACE2 catalytic activity.

公开(公告)号：US20240424088A1

公开(公告)日：2024-12-26

申请号：US18882219

申请日：2024-09-11

Applicant: ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong

IPC: A61K39/215 ,  A61K39/00 ,  A61P31/14

Abstract: Recombinant SARS-CoV2 vaccine compositions and methods are presented that have unexpected cross-reactivity against a variety of other coronaviruses, and particularly against SARS-CoV1, MERS-CoV, OC43-CoV, and HKU1-CoV in addition to significant reactivity against SARS-CoV2A. Moreover, the vaccine compositions presented herein also produced cross-reactive memory B cells as well as cross-reactive memory T cells with cross-reactivity spanning a relatively wide range of different coronaviruses.